Floatz Rating
B60/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07509034CT.gov Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease | — | Not Yet Recruiting | — | — | — |
NCT07570563CT.gov Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. | — | Recruiting | — | — | — |
NCT07415031CT.gov A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | — | Recruiting | — | — | — |
NCT07498725CT.gov A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07610941CT.gov Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies | — | Recruiting | — | — | — |
NCT07487597CT.gov Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07404332CT.gov 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors | — | Recruiting | — | — | — |
NCT07342738CT.gov TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06885697CT.gov Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | — | Recruiting | — | — | — |
NCT07108140CT.gov Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors | — | Terminated | — | — | — |
Show 180 more trialsShow fewer
NCT06939270CT.gov CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06549946CT.gov Ixovex-1 Single Agent and Combination Therapy | — | Recruiting | — | — | — |
NCT06576037CT.gov Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin | — | Recruiting | — | — | — |
NCT06551142CT.gov A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) | — | Recruiting | — | — | — |
NCT06171178CT.gov A Study of ASP1012 in Adults With Solid Tumors | — | Terminated | — | — | — |
NCT06394622CT.gov A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors | — | Recruiting | — | — | — |
NCT06327997CT.gov An Exploratory Study by Fast CAR T Cells | — | Recruiting | — | — | — |
NCT06205706CT.gov BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06049212CT.gov Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) | — | Active Not Recruiting | — | — | — |
NCT06066424CT.gov Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | — | Recruiting | — | — | — |
NCT06036836CT.gov Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | — | Completed | — | — | — |
NCT06468943CT.gov Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | — | Enrolling By Invitation | — | — | — |
NCT05672459CT.gov A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06249256CT.gov An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells | — | Recruiting | — | — | — |
NCT05831033CT.gov Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05859074CT.gov A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | — | Recruiting | — | — | — |
NCT05491317CT.gov A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT05775666CT.gov UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors | — | Unknown | — | — | — |
NCT05642780CT.gov SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05653882CT.gov A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05431582CT.gov Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | — | Withdrawn | — | — | — |
NCT05649618CT.gov TIL Cells for the Treatment of the Advanced Solid Tumors Patients | — | Unknown | — | — | — |
NCT05648994CT.gov TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05620134CT.gov Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05798546CT.gov Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) | — | Unknown | — | — | — |
NCT05514444CT.gov Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) | — | Completed | — | — | — |
NCT05419817CT.gov Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | — | Withdrawn | — | — | — |
NCT05470283CT.gov Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT05378425CT.gov A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | — | Active Not Recruiting | — | — | — |
NCT05273554CT.gov A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma | — | Active Not Recruiting | — | — | — |
NCT05382559CT.gov A Study of ASP3082 in Adults With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05101070CT.gov S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05346484CT.gov A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05176509CT.gov A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors | — | Completed | — | — | — |
NCT05147493CT.gov A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | — | Unknown | — | — | — |
NCT05284968CT.gov RD07 Cell Injection in the Treatment of Patients With Advanced Claudin18.2 Positive Solid Tumors | — | Unknown | — | — | — |
NCT05320588CT.gov A Study in Patients With Advanced Cancers | — | Recruiting | — | — | — |
NCT05082610CT.gov A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04955743CT.gov Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT05064280CT.gov Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | — | Recruiting | — | — | — |
NCT05155215CT.gov Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma | — | Unknown | — | — | — |
NCT05128487CT.gov A Study of NDI 1150-101 in Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04958239CT.gov A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | — | Active Not Recruiting | — | — | — |
NCT04787042CT.gov Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | — | Recruiting | — | — | — |
NCT04541108CT.gov Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | — | Active Not Recruiting | — | — | — |
NCT04840394CT.gov Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04937153CT.gov GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies | — | Completed | — | — | — |
NCT04717375CT.gov Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04720976CT.gov JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT06048705CT.gov Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04729348CT.gov Pembrolizumab And Lenvatinib In Leptomeningeal Metastases | — | Terminated | — | — | — |
NCT04753177CT.gov The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer | — | Unknown | — | — | — |
NCT04526509CT.gov Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04627740CT.gov Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors | — | Completed | — | — | — |
NCT05373147CT.gov αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | — | Unknown | — | — | — |
NCT04585750CT.gov The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | — | Recruiting | — | — | — |
NCT04469530CT.gov Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors | — | Recruiting | — | — | — |
NCT04222972CT.gov A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT04420884CT.gov A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT04511871CT.gov A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04443088CT.gov An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04319757CT.gov ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | — | Completed | — | — | — |
NCT04239092CT.gov 9-ING-41 in Pediatric Patients With Refractory Malignancies. | — | Terminated | — | — | — |
NCT04301011CT.gov Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | — | Terminated | — | — | — |
NCT04348916CT.gov Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors | — | Terminated | — | — | — |
NCT04344795CT.gov Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT03658785CT.gov Immunotherapy for the Treatment of Advanced Solid Tumor | — | Recruiting | — | — | — |
NCT04348643CT.gov Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | — | Unknown | — | — | — |
NCT04205227CT.gov ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04029688CT.gov A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | — | Terminated | — | — | — |
NCT03967223CT.gov Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04157517CT.gov A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT04123366CT.gov Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) | — | Active Not Recruiting | — | — | — |
NCT04099277CT.gov A Study of LY3435151 in Participants With Solid Tumors | — | Terminated | — | — | — |
NCT03954067CT.gov A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors | — | Completed | — | — | — |
NCT03948763CT.gov A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | — | Terminated | — | — | — |
NCT03918278CT.gov A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) | — | Completed | — | — | — |
NCT03829254CT.gov A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | — | Recruiting | — | — | — |
NCT03709680CT.gov Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03861403CT.gov A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03960060CT.gov A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors | — | Terminated | — | — | — |
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03934814CT.gov Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | — | Completed | — | — | — |
NCT03884556CT.gov TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | — | Completed | — | — | — |
NCT03647163CT.gov Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03894540CT.gov Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours | — | Terminated | — | — | — |
NCT03832569CT.gov Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03709706CT.gov Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab | — | Terminated | — | — | — |
NCT03588039CT.gov Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03733587CT.gov GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors | — | Completed | — | — | — |
NCT03511222CT.gov Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03617432CT.gov Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients | — | Unknown | — | — | — |
NCT03486873CT.gov Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | — | Recruiting | — | — | — |
NCT03590054CT.gov Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | — | Completed | — | — | — |
NCT03564691CT.gov Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) | — | Completed | — | — | — |
NCT03530397CT.gov A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03473925CT.gov Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | — | Completed | — | — | — |
NCT03447314CT.gov Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03383094CT.gov Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | — | Active Not Recruiting | — | — | — |
NCT03428802CT.gov Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | — | Active Not Recruiting | — | — | — |
NCT03361228CT.gov A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03396445CT.gov Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | — | Completed | — | — | — |
NCT03486301CT.gov BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab | — | Completed | — | — | — |
NCT02834052CT.gov Pembrolizumab + Poly-ICLC in MRP Colon Cancer | — | Completed | — | — | — |
NCT03139370CT.gov Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers | — | Terminated | — | — | — |
NCT03364049CT.gov Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) | — | Completed | — | — | — |
NCT03229278CT.gov Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | — | Completed | — | — | — |
NCT03308942CT.gov Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants | — | Completed | — | — | — |
NCT03249792CT.gov Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) | — | Terminated | — | — | — |
NCT03168438CT.gov Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | — | Terminated | — | — | — |
NCT03313778CT.gov Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02587962CT.gov Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors | — | Terminated | — | — | — |
NCT02876510CT.gov ACTolog in Patients With Solid Cancers | — | Completed | — | — | — |
NCT03099161CT.gov Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) | — | Terminated | — | — | — |
NCT03085914CT.gov A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) | — | Completed | — | — | — |
NCT02987166CT.gov HDCRT Plus Pembrolizumab in Advanced Malignancies | — | Completed | — | — | — |
NCT02959437CT.gov Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | — | Terminated | — | — | — |
NCT03010176CT.gov Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) | — | Completed | — | — | — |
NCT03013218CT.gov A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | — | Completed | — | — | — |
NCT02972034CT.gov Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) | — | Terminated | — | — | — |
NCT03006887CT.gov Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors | — | Completed | — | — | — |
NCT02964013CT.gov Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001) | — | Completed | — | — | — |
NCT02901145CT.gov Nivolumab in Relapsed Pediatric Solid Tumors | — | Unknown | — | — | — |
NCT02798406CT.gov Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects | — | Completed | — | — | — |
NCT02909452CT.gov Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02903914CT.gov Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | — | Completed | — | — | — |
NCT02909348CT.gov Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab | — | Completed | — | — | — |
NCT02783300CT.gov An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT02721732CT.gov Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | — | Active Not Recruiting | — | — | — |
NCT02723955CT.gov Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) | — | Completed | — | — | — |
NCT02432963CT.gov Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | — | Active Not Recruiting | — | — | — |
NCT02719691CT.gov Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer | — | Completed | — | — | — |
NCT02720068CT.gov Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) | — | Completed | — | — | — |
NCT02657889CT.gov Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | — | Completed | — | — | — |
NCT02546531CT.gov Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | — | Completed | — | — | — |
NCT02588612CT.gov Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02675946CT.gov CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | — | Unknown | — | — | — |
NCT02646748CT.gov Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02608385CT.gov Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02660281CT.gov URMC Related Haplo-identical Donor BMT | — | Completed | — | — | — |
NCT02521844CT.gov A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours | — | Active Not Recruiting | — | — | — |
NCT02630368CT.gov A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) | — | Unknown | — | — | — |
NCT02528357CT.gov GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1) | — | Completed | — | — | — |
NCT02653196CT.gov A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors | — | Terminated | — | — | — |
NCT02498912CT.gov Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02501096CT.gov A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors | — | Completed | — | — | — |
NCT03016806CT.gov Umbilical Cord Blood Transplantation From Unrelated Donors | — | Recruiting | — | — | — |
NCT02332668CT.gov A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | — | Recruiting | — | — | — |
NCT02366546CT.gov Investigator Initiated Phase 1 Study of TBI-1301 | — | Unknown | — | — | — |
NCT02393248CT.gov Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | — | Terminated | — | — | — |
NCT02517918CT.gov Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma | — | Completed | — | — | — |
NCT02354547CT.gov A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors | — | Suspended | — | — | — |
NCT02274610CT.gov Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer | — | Completed | — | — | — |
NCT02253420CT.gov COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients | — | Completed | — | — | — |
NCT02265510CT.gov An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02306837CT.gov Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies | — | Unknown | — | — | — |
NCT02446431CT.gov Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence | — | Recruiting | — | — | — |
NCT02132754CT.gov Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) | — | Completed | — | — | — |
NCT02130466CT.gov A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | — | Completed | — | — | — |
NCT02096614CT.gov Investigator Initiated Phase 1 Study of TBI-1201 | — | Completed | — | — | — |
NCT02054806CT.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) | — | Completed | — | — | — |
NCT02120118CT.gov Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors | — | Withdrawn | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01844583CT.gov Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib | — | Completed | — | — | — |
NCT01875601CT.gov NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01848834CT.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) | — | Completed | — | — | — |
NCT01411410CT.gov Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer | — | Completed | — | — | — |
NCT01346358CT.gov A Study of IMC-CS4 in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00960063CT.gov A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | — | Terminated | — | — | — |
NCT01336582CT.gov Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer | — | Completed | — | — | — |
NCT00884546CT.gov Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT03402295CT.gov Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation | — | Completed | — | — | — |
NCT01445522CT.gov ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer | — | Completed | — | — | — |
NCT00470613CT.gov Safety Study of Infusion of SGT-53 to Treat Solid Tumors | — | Completed | — | — | — |
NCT00586560CT.gov Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010) | — | Completed | — | — | — |
NCT00425516CT.gov Breast Cancer Treated by Neoadjuvant Chemotherapy | — | Completed | — | — | — |
NCT00578942CT.gov Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath | — | Completed | — | — | — |
NCT00628732CT.gov A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors | — | Completed | — | — | — |
NCT00580034CT.gov Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath | — | Completed | — | — | — |
NCT00251407CT.gov Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | National Cancer Institute (NCI) | P3 | B · 60 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →